FDA fast-tracks biosimilar approvals, automatically allowing drug substitutions
S. 1954 — Biosimilar Red Tape Elimination Act · Filed by Mike Lee (R-UT) · 5 cosponsors · Introduced Jun 4, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill streamlines FDA approval for biosimilar drugs (cheaper copies of expensive biologic medicines) by eliminating the requirement that biosimilars prove they are 'interchangeable' with the original drug before being approved. Instead, all biosimilars approved under the new standard are automatically deemed interchangeable upon licensure, removing a regulatory hurdle that has delayed patient access to lower-cost alternatives. The bill preserves existing exclusivity periods for biosimilars already approved under the old rules.
Why we flagged it
The bill's core function is to simplify FDA approval pathways for biosimilar drugs by removing the interchangeability determination step and automatically deeming approved biosimilars interchangeable. This is a deregulatory measure that accelerates market entry for generic biologics.
What the text implies
- Automatic interchangeability may reduce pharmacist discretion and physician control over substitution decisions, potentially affecting clinical outcomes if biosimilars have subtle differences from reference products that emerge post-approval.
- The 60-day transition period creates a narrow window during which biosimilars approved before enactment must comply with new rules, potentially disrupting existing market arrangements and exclusivity agreements.
- Removal of interchangeability determination may weaken the evidentiary record available to patients, providers, and payers for assessing whether a specific biosimilar is truly equivalent to the reference product in real-world use.
- The bill does not address how state pharmacy laws or insurance formularies will handle automatic interchangeability, creating potential friction between federal approval and state/payer implementation.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary patients and consumers benefit from faster access to cheaper biosimilar alternatives to expensive biologic drugs, which can reduce out-of-pocket costs and increase competition in the biologic market. The removal of the interchangeability determination requirement lowers regulatory barriers without eliminating safety review—the FDA still evaluates biosimilarity before approval.
Who stands to gain
- biosimilar manufacturers
- generic drug companies
- pharmacy benefit managers (PBMs)
- health insurers
- large employers self-insuring health plans
Named in the bill
FDA, HHS, Public Health Service Act Section 351, Federal Food, Drug, and Cosmetic Act Section 505B, biosimilar manufacturers, reference product manufacturers, pharmacists, healthcare providers
Where it stands
5 cosponsors: 3 Democrats, 2 Republicans.
- Jun 4, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Jun 4, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
- Jun 17, 2026 — Reported out of committee · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
30 lobbying clients named this bill on 41 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $29,966,000 in lobbying spend. A filing names 18 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 98% of bills with at least one filing.
Mike Lee, the sponsor, reported $241,000 in PAC receipts in the 2026 cycle.
- Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
- Amgen Inc — $2,440,000 on 1 filing
- Blue Cross and Blue Shield Association — $2,430,000 on 2 filings
- Johnson & Johnson Services Inc — $1,440,000 on 1 filing
- Cambia Health Solutions — $1,330,000 on 2 filings
Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (5,929 characters) on Aug 20, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 22, 2026 · page rendered 2026-10-20.
“FDA fast-tracks biosimilar approvals, automatically allowing drug substitutions” QuorumCivic. https://share.quorumcivic.app/bill/119/s1954 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.